Medigen Biotechnology Corp. (TPEX:3176)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.25
-0.05 (-0.17%)
Jul 16, 2025, 2:31 PM CST

Medigen Biotechnology Company Description

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan.

It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells.

It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States.

Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.

Medigen Biotechnology Corp.
CountryTaiwan
Founded1999
IndustryBiotechnology
SectorHealthcare
CEOShun-Lang Chang

Contact Details

Address:
No.3, Park Street
Taipei, 11503
Taiwan
Phone886 2 7736 1234
Websitemedigen.com.tw

Stock Details

Ticker Symbol3176
ExchangeTaipei Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyTWD
ISIN NumberTW0003176004
SIC Code2836

Key Executives

NamePosition
Shun-Lang ChangGeneral Manager
Ya-Ling ChiangAssistant Vice President of Operations and Management Department
Chin-Yen ChenAssistant Vice President of Drug Development Department
Feng-Hua ChenFinance Manager and Accounting Officer